The AIM-listed biotech reports 77% progression-free survival at 20 months, well ahead of the standard of care Scancell ...

CEO Jeremy Skillington joined Proactive's Stephen Gunnion to discuss the ...

The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds.

Greatland Resources Ltd (AIM:GGP, OTC:GRLGF, FRA:G8G, ASX:GGP), in its quarterly activities report, told investors it had ...

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, is advancing partnering ...

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the gene therapy developer, has signed additional confidentiality ...

Active Energy Group PLC (AIM:AEG, OTCID:AEUSF) said its 8MVA site in the UAE is set to become the initial pilot deployment ...

Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF), the miner developing the Zulu Lithium and Tantalum Project in Zimbabwe, ...

FTSE battles higher The FTSE 100 has fought its way into the green, up 20 points at 10,341. BP and Shell are doing a lot of ...

Barclays leads FTSE lower at open The FTSE 100 has opened very slightly lower, pulled down by Barclays and housebuilders. In ...

BP profit surges BP has reported a return to profit in the first quarter, helped by stronger trading and refining as oil ...

The AIM-listed biotech's SIRT6 programme is attracting a widening group of Tier-1 industry evaluators, sending shares to ...